ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002 - First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...

ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board - Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 –...

ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material...

ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002 - Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...